Emerging role of PPAR ligands in the management of diabetic nephropathy.

Balakumar, Pitchai; Arora, Mandeep Kumar; Singh, Manjeet

Balakumar, Pitchai; Arora, Mandeep Kumar; Singh, Manjeet.

Affiliation

Balakumar P; Cardiovascular Pharmacology Division, ISF College of Pharmacy, Moga 142001, Punjab, India. pbala2006@gmail.com

Pharmacol Res ; 60(3): 170-3, 2009 Sep.

Article in En | MEDLINE | ID: mdl-19646656

ABSTRACT

ABSTRACT

Diabetic nephropathy is a leading cause of morbidity and mortality in hyperglycemic patients. Angiotensin converting enzyme inhibitors and angiotensin-II AT(1) receptor blockers are currently employed to treat patients with diabetic nephropathy; but these agents are considered to be inadequate to control the symptoms of diabetic nephropathy. Recent studies suggest that PPAR ligands are promising agents to prevent the progression of diabetic nephropathy. In the present review, we discussed the novel role of PPARalpha and PPARgamma agonists in the management of diabetic nephropathy.

Subject(s)

Diabetic Nephropathies/drug therapy; Peroxisome Proliferator-Activated Receptors/agonists; Animals; Humans; Ligands; Peroxisome Proliferator-Activated Receptors/physiology; Protein Isoforms

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Peroxisome Proliferator-Activated Receptors / Diabetic Nephropathies Limits: Animals / Humans Language: En Journal: Pharmacol Res Journal subject: FARMACOLOGIA Year: 2009 Document type: Article Affiliation country: India

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google